F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have discovered new heteroarylphenyl ether derivatives acting as cyclin-dependent kinase CDK8/cyclin C inhibitors. As such, they are reported to be useful for the treatment of graft-vs.-host disease, transplant rejection, multiple sclerosis, rheumatoid arthritis, atopic dermatitis, psoriasis, amyotrophic lateral sclerosis and stroke, among others.
Serine/threonine-protein kinase WNK1 inhibitors have been described in a Dania Therapeutics ApS patent as potentially useful for the treatment of cancer and hypertension.
Pelemed Co. Ltd. has prepared pyrrolotriazine derivatives acting as tyrosine-protein kinase Yes (YES1) inhibitors reported to be useful for the treatment of cancer.
Work at Libra Therapeutics Inc. has led to the identification of new mucolipin-1 (MCOLN1; TRPML1) activators reported to be useful for the treatment of metabolic diseases, infections, hematologic diseases, inflammation, cardiovascular, eye, neurological and renal disorders, among others.
The first filing in the name of Grand Rapids, Mich.-headquartered Corium Innovations Inc. confirms the company formerly known as Corium Pharma Solutions Inc. is developing treatments for multiple sclerosis and ulcerative colitis that employ its proprietary Corplex transdermal patch technology.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has prepared and tested Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Cytosinlab Therapeutics Co. Ltd. has synthesized G/T mismatch-specific thymine DNA glycosylase (TDG) inhibitors reported to be useful for the treatment of cancer.
Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, osteosarcoma, glaucoma, ocular hypertension, dry eye, uveitis and age-related macular degeneration, among others.
RSS
